398 related articles for article (PubMed ID: 9105710)
1. Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y.
Bischoff A; Avramidis P; Erdbrügger W; Münter K; Michel MC
Br J Pharmacol; 1997 Apr; 120(7):1335-43. PubMed ID: 9105710
[TBL] [Abstract][Full Text] [Related]
2. Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226.
Kask A; Rägo L; Harro J
Br J Pharmacol; 1998 Aug; 124(7):1507-15. PubMed ID: 9723965
[TBL] [Abstract][Full Text] [Related]
3. Characterization of neuropeptide Y-induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding?
Iyengar S; Li DL; Simmons RM
J Pharmacol Exp Ther; 1999 May; 289(2):1031-40. PubMed ID: 10215684
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptide Y lowers blood glucose in anaesthetized rats via a Y5 receptor subtype.
Bischoff A; Michel MC
Endocrinology; 1998 Jun; 139(6):3018-21. PubMed ID: 9607814
[TBL] [Abstract][Full Text] [Related]
5. The neuropeptide Y (NPY) Y1 receptor antagonist BIBP 3226: equal effects on vascular responses to exogenous and endogenous NPY in the pig in vivo.
Malmström RE; Balmér KC; Lundberg JM
Br J Pharmacol; 1997 Jun; 121(3):595-603. PubMed ID: 9179405
[TBL] [Abstract][Full Text] [Related]
6. Indomethacin inhibits the natriuretic effects of neuropeptide Y in anesthetized rats.
Bischoff A; Limmroth V; Michel MC
J Pharmacol Exp Ther; 1998 Aug; 286(2):704-8. PubMed ID: 9694924
[TBL] [Abstract][Full Text] [Related]
7. Vascular neuropeptide Y Y1-receptors in the rat kidney: vasoconstrictor effects and expression of Y1-receptor mRNA.
Modin A; Malmström RE; Meister B
Neuropeptides; 1999 Aug; 33(4):253-9. PubMed ID: 10657500
[TBL] [Abstract][Full Text] [Related]
8. Neuropeptide Y stimulates bile secretion via Y1 receptor in the left dorsal vagal complex in rats.
Yoneda M; Nakamura K; Yokohama S; Tamori K; Sato Y; Aso K; Aoshima M; Kono T; Makino I
Hepatology; 1998 Sep; 28(3):670-6. PubMed ID: 9731557
[TBL] [Abstract][Full Text] [Related]
9. In vivo receptor characterization of neuropeptide Y-induced effects in consecutive vascular sections of cat skeletal muscle.
Ekelund U; Erlinge D
Br J Pharmacol; 1997 Feb; 120(3):387-92. PubMed ID: 9031740
[TBL] [Abstract][Full Text] [Related]
10. Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226.
Abounader R; Villemure JG; Hamel E
Br J Pharmacol; 1995 Oct; 116(4):2245-50. PubMed ID: 8564255
[TBL] [Abstract][Full Text] [Related]
11. Neuropeptide Y enhances potassium excretion by mechanisms distinct from those controlling sodium excretion.
Bischoff A; Michel MC
Can J Physiol Pharmacol; 2000 Feb; 78(2):93-9. PubMed ID: 10737671
[TBL] [Abstract][Full Text] [Related]
12. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.
Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML
Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275
[TBL] [Abstract][Full Text] [Related]
13. Neuropeptide Y-enhanced diuresis and natriuresis in anaesthetized rats is independent of renal blood flow reduction.
Bischoff A; Erdbrügger W; Smits J; Michel MC
J Physiol; 1996 Sep; 495 ( Pt 2)(Pt 2):525-34. PubMed ID: 8887762
[TBL] [Abstract][Full Text] [Related]
14. The ability of neuropeptide Y to mediate responses in the murine cutaneous microvasculature: an analysis of the contribution of Y1 and Y2 receptors.
Chu DQ; Cox HM; Costa SK; Herzog H; Brain SD
Br J Pharmacol; 2003 Sep; 140(2):422-30. PubMed ID: 12970079
[TBL] [Abstract][Full Text] [Related]
15. Neuropeptide Y (NPY) and peptide YY (PYY) effects in the epididymis of the guinea-pig: evidence of a pre-junctional PYY-selective receptor.
Haynes JM; Hill SJ; Selbie LA
Br J Pharmacol; 1997 Dec; 122(7):1530-6. PubMed ID: 9421306
[TBL] [Abstract][Full Text] [Related]
16. Neuropeptide Y Y1 receptor mechanisms in sympathetic vascular control.
Malmström RE
Acta Physiol Scand Suppl; 1997; 636():1-55. PubMed ID: 9179320
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
Doods HN; Wienen W; Entzeroth M; Rudolf K; Eberlein W; Engel W; Wieland HA
J Pharmacol Exp Ther; 1995 Oct; 275(1):136-42. PubMed ID: 7562541
[TBL] [Abstract][Full Text] [Related]
18. Bradykinin may be involved in neuropeptide Y-induced diuresis, natriuresis, and calciuresis.
Bischoff A; Rascher W; Michel MC
Am J Physiol; 1998 Oct; 275(4):F502-9. PubMed ID: 9755121
[TBL] [Abstract][Full Text] [Related]
19. PYY preference is a common characteristic of neuropeptide Y receptors expressed in human, rat, and mouse gastrointestinal epithelia.
Holliday ND; Pollock EL; Tough IR; Cox HM
Can J Physiol Pharmacol; 2000 Feb; 78(2):126-33. PubMed ID: 10737675
[TBL] [Abstract][Full Text] [Related]
20. Distribution of [Leu31,Pro34]NPY-sensitive, BIBP3226-insensitive [125I]PYY(3-36) binding sites in rat brain: possible relationship to Y5 NPY receptors.
Widdowson PS; Buckingham R; Williams G
Brain Res; 1997 Dec; 778(1):242-50. PubMed ID: 9462897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
